Founded in 2003 by former executives of Novazyme Pharmaceuticals, Cytovance delivers a broad menu of specialized contract biological manufacturing services that help companies such as Oklahoma City's Selexys Pharmaceuticals manufacture drugs for clinical trials.
Today, Cytovance provides its contract manufacturing services to more than 32 clients worldwide. It has expanded its presence in the Research Park to four buildings, including the manufacturing plant.
“When I started in 2008, we were at $1.5 million in revenue,” Head said recently from his office in the 800 Building at the Research Park. “Now, we are projecting $22.5 million for this year. Incredible growth," says Darren Head, president and CEO of Cytovance Biologics.
So what prompted such explosive growth in an Oklahoma-based life science company? Read more